Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience

Prostate

Volumn 73, Issue 15, 2013, Pages 1673-1680

  Pierorazio, Phillip M ^a   Gorin, Michael A ^a   Ross, Ashley E ^a   Feng, Zhaoyong ^a   Trock, Bruce J ^a   Schaeffer, Edward M ^a   Han, Misop ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a   Walsh, Patrick C ^a   Bivalacqua, Trinity J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

lymph node metastases; prostate cancer; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; PELVIS LYMPH NODE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL PREDICTION; SURVIVAL TIME; TREATMENT OUTCOME;

LYMPH NODE METASTASES; PROSTATE CANCER; RADICAL PROSTATECTOMY;

ADULT; AGED; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884902194     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22702     Document Type: Article

References (22)

1. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ,. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-875.
2. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG,. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 2004; 172: 2252-2255.
3. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML,. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection, and adjuvant therapy. Eur Urol 2009; 55: 261-270.
4. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE,. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54: 344-352.
5. Schiavina R, Borghesi M, Brunocilla E, Manferrari F, Fiorentino M, Vagnoni V, Baccos A, Pultrone CV, Rocca GC, Rizzi S, Martorana G,. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: Identification of risk categories according to number of positive nodes and Gleason score. BJU Int 2013; 111 (8): 1237-1244.
6. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC,. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: Results of long-term followup. J Urol 2004; 172: 1860-1864.
7. Prostate Cancer, in Clinical Practice Guidelines in Oncology, N.C.C. Network, Editor. 2013.
8. Epstein JI, Pizov G, Walsh PC,. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71 (11): 3582-3593.
9. Bochner BH, Herr HW, Reuter VE,. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 2001; 166 (6): 2295-2296.
10. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ,. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24: 2735-2742.
11. Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H, Livak KJ, Gallagher RE, Mandeli J,. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 2006; 24: 3081-3088.
12. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML,. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178: 864-870 discussion 870-1.
13. Carlsson SV, Tafe LJ, Chade DC, Sjoberg DD, Passoni N, Shariat SF, Eastham J, Scardino PT, Fine SW, Touijer KA,. Pathological features of lymph node metastases in predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol 2012; 189 (4): 1314-1318.
14. Epstein JI, Allsbrook WC, Amin MB Jr, Egevad LL,. The 2005 International society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29 (9): 1228-1242.
15. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML,. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int 2008; 101 (3): 299-304.
16. Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T, Studer UE,. The template of the primary lymphatic landing sites of the prostate should be revisited: Results of a multimodality mapping study. Eur Urol 2008; 53: 118-125.
17. Gallina A, Briganti A, Suardi N, Abdollah F, Capitanio U, Castiglione F, Pellucchi F, Capogrosso P, Dell'Oglio P, Nini A, Colombo R, Guazzoni G, Rigatti P, Montorsi F,. Should an extended nodal template for high-risk prostate cancer always include removal of common iliac lymph nodes?, in American Urologic Assocation (AUA) Annual Meeting. 2012 Atlanta, GA; USA.
18. Briganti A, Chun FK, Salonia A, Gallina A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI,. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 2007; 69: 147-151.
19. Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, Roscigno M, Zanni G, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI,. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006-1013.
20. Bader P, Burkhard FC, Markwalder R, Studer UE,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure ? J Urol 2003; 169 (3): 849-854.
21. Swanson GP, Thompson IM, Basler J,. Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome. Cancer 2006; 107 (3): 439-450.
22. Fleischmann A, Schobinger S, Schumacher M, Thalmann G.N, Studer U.E,. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 2009; 69 (4): 352-362.